Literature DB >> 26500896

A Study on the Level of Oxidative Stress and Inflammatory Markers in Type 2 Diabetes Mellitus Patients with Different Treatment Modalities.

Siva Prasad Palem1, Philips Abraham2.   

Abstract

INTRODUCTION: The prevalence of type 2 diabetes mellitus is increasing worldwide in all the age group. UKPDS study had shown that good glycaemic control is maintained by the administration of insulin in addition to hypoglycaemic drugs. But, hyperinsulinemia might cause vascular complications in T2DM. Oxidative stress and inflammation are common in diabetes and plays an important role in vascular complications. AIM: The study has been designed to estimate and compare the level of oxidative stress and inflammation in type 2 diabetic patients under different treatment modalities.
MATERIALS AND METHODS: Sixty Type 2 diabetic subjects undergoing treatment were selected from Government Hospital and VMKV Medical College & Hospital at Salem. The subjects were divided into two groups based on treatment modalities, hypoglycaemic drugs subjects as Group-I (30) and hypoglycaemic drugs & Insulin subjects in Group-II (30). BMI was calculated by standard formula and Fasting blood sugar (FBS), postprandial blood sugar (PPBS), glycated haemoglobin (HbA1c), Lipid profile, oxidative stress (MDA) and inflammatory markers were measured by well established methods. SPSS 16.0 version was used for statistical analysis. RESULT: In our study we have found significantly high levels of BMI, MDA and hsCRP (25.5±2.79, 2.73±1.65, 1.98±0.85) in Group II subjects when compared to Group I subjects (23.4±3.09, 2.23±1.76, 1.168±1.124).
CONCLUSION: Since risk factors like BMI, MDA and hsCRP were high in Diabetes mellitus patients on both oral hypoglycaemic drugs and insulin, they are more susceptible to cardiovascular diseases. Evaluation of these markers at regular interval can reduce the incidence of vascular complications in Type 2 DM patients.

Entities:  

Keywords:  Body Mass Index (BMI); Glycosylated Haemoglobin (HbA1c); High sensitive C-reactive protein (hsCRP); Hypoglycaemic drugs & Insulin (HGDI); Hypoglycaemic drugs (HGD); Malondialdehyde (MDA)

Year:  2015        PMID: 26500896      PMCID: PMC4606225          DOI: 10.7860/JCDR/2015/14218.6449

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  25 in total

1.  Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  S E Inzucchi; R M Bergenstal; J B Buse; M Diamant; E Ferrannini; M Nauck; A L Peters; A Tsapas; R Wender; D R Matthews
Journal:  Diabetologia       Date:  2012-04-20       Impact factor: 10.122

2.  Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes.

Authors:  Frederico G S Toledo; Allan D Sniderman; David E Kelley
Journal:  Diabetes Care       Date:  2006-08       Impact factor: 19.112

Review 3.  Review of current and emerging therapies in type 2 diabetes mellitus.

Authors:  Nissa Mazzola
Journal:  Am J Manag Care       Date:  2012-01       Impact factor: 2.229

4.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

Authors:  A Festa; R D'Agostino; G Howard; L Mykkänen; R P Tracy; S M Haffner
Journal:  Circulation       Date:  2000-07-04       Impact factor: 29.690

5.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.

Authors:  John Danesh; Jeremy G Wheeler; Gideon M Hirschfield; Shinichi Eda; Gudny Eiriksdottir; Ann Rumley; Gordon D O Lowe; Mark B Pepys; Vilmundur Gudnason
Journal:  N Engl J Med       Date:  2004-04-01       Impact factor: 91.245

6.  Differential effects of insulin deficiency on albumin and fibrinogen synthesis in humans.

Authors:  P De Feo; M G Gaisano; M W Haymond
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

7.  Oxidative stress in non-insulin-dependent diabetes mellitus (NIDDM) patients.

Authors:  Vadde Ramakrishna; Rama Jailkhani
Journal:  Acta Diabetol       Date:  2007-10-09       Impact factor: 4.280

8.  The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

Authors:  Matthew C Riddle; Julio Rosenstock; John Gerich
Journal:  Diabetes Care       Date:  2003-11       Impact factor: 19.112

9.  Elevated serum C-reactive protein level and microalbuminuria in patients with type 2 diabetes mellitus.

Authors:  Mohammad Javad Mojahedi Mojahedi; Shokoofeh Bonakdaran; Maryam Hami; Mohammad Reza Sheikhian; Mohammad Taghi Shakeri; Hossein Aiatollahi
Journal:  Iran J Kidney Dis       Date:  2009-01       Impact factor: 0.892

10.  Inflammation in the pathogenesis of microvascular complications in diabetes.

Authors:  Dung V Nguyen; Lynn C Shaw; Maria B Grant
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-21       Impact factor: 5.555

View more
  7 in total

1.  The effect of synbiotic supplementation on atherogenic indices, hs-CRP, and malondialdehyde, as major CVD-related parameters, in women with gestational diabetes mellitus: a secondary data-analysis of a randomized double-blind, placebo-controlled study.

Authors:  Zohoor Nabhani; Elham Razmpoosh; Cain C T Clark; Nazanin Goudarzi; Alemeh Hariri Far
Journal:  Diabetol Metab Syndr       Date:  2022-06-21       Impact factor: 5.395

2.  Anti-diabetic and antioxidant effect of cinnamon in poorly controlled type-2 diabetic Iraqi patients: A randomized, placebo-controlled clinical trial.

Authors:  Ahmed Salih Sahib
Journal:  J Intercult Ethnopharmacol       Date:  2016-02-21

3.  Could consumption of yam (Dioscorea) or its extract be beneficial in controlling glycaemia: a systematic review.

Authors:  Waad Z Alharazi; Anthony McGowen; Peter Rose; Preeti H Jethwa
Journal:  Br J Nutr       Date:  2021-09-15       Impact factor: 4.125

4.  Genetic variants of nuclear factor erythroid-derived 2-like 2 associated with the complications in Han descents with type 2 diabetes mellitus of Northeast China.

Authors:  Xiaohong Xu; Jing Sun; Xiaomin Chang; Ji Wang; Manyu Luo; Kupper A Wintergerst; Lining Miao; Lu Cai
Journal:  J Cell Mol Med       Date:  2016-07-04       Impact factor: 5.310

Review 5.  Coadjuvants in the Diabetic Complications: Nutraceuticals and Drugs with Pleiotropic Effects.

Authors:  Thiago Melo Costa Pereira; Fabio Silva Pimenta; Marcella Lima Porto; Marcelo Perim Baldo; Bianca Prandi Campagnaro; Agata Lages Gava; Silvana Santos Meyrelles; Elisardo Corral Vasquez
Journal:  Int J Mol Sci       Date:  2016-08-05       Impact factor: 5.923

6.  Effects of a Multispecies Probiotic Mixture on Glycemic Control and Inflammatory Status in Women with Gestational Diabetes: A Randomized Controlled Clinical Trial.

Authors:  Sadegh Jafarnejad; Sadaf Saremi; Farzan Jafarnejad; Arman Arab
Journal:  J Nutr Metab       Date:  2016-06-26

7.  Protective Effects of Reduced Beta 2 Glycoprotein I on Liver Injury in Streptozotocin (STZ)-Diabetic Rats by Activation of AMP-Activated Protein Kinase.

Authors:  Jing-Yun Zhang; Chun-Jun Li; Qiu-Mei Zhang; Pei Yu; Jian-Ying Shi; Guang-Jie Tang; Lin-Lin Ma; De-Min Yu
Journal:  Med Sci Monit       Date:  2018-10-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.